ACC 2022 Conference Coverage
Avatar

ACC 2022: An Overview of SGLT2i and GLP1 RA Use in Cardiovascular Disease

By ACC 2022 Conference Coverage FEATURING Robert Eckel
By ACC 2022 Conference Coverage FEATURING Robert Eckel
1,560 views
May 24, 2022
1 Comment
Login to view comments. Click here to Login

Featured Video

18:06
Lilly Obesity

Getting Patients Started with an Obesity Treatment Option for Adults

Feat. E. Lazarus

Featured Video

18:06
Lilly Obesity

Getting Patients Started with an Obesity Treatment Option for Adults

Feat. E. Lazarus

Related Content

AUTOPLAY
64:45
Symposium on Diabetes and Cancer 2017: Novel Links and Treatments

Primer on Diabetes Management

Feat. S. Inzucchi
11:37
ACC 2022 Conference Coverage

ACC 2022: An Embarrassment of Riches - Updated Guideline Recommendat…

Feat. P. Heidenreich
11:25
ACC 2023 Conference Coverage

ACC 2023: SGLT2i Use - Dos and Don'ts

Feat. A. Armbruster
18:43
ASPC 2019 Congress on CVD Prevention

Diabetes Treatment Guidelines Finally Have Entered the 21st Century …

Feat. R. DeFronzo
15:06
Robert Busch

GLP-1/GIP Update: Stay Tuned... The Best is Yet to Come!!

26:01
Cardiology Fiesta 2017

Renal, Metabolic and Cardiovascular Considerations of SGLT2 Inhibiti…

Feat. R. DeFronzo
12:26
Juan Frias

SURPASS 2: Tirzepatide Versus Once-Weekly Semaglutide

15:33
Ken Fujioka

Could GLP-1's be a 'Game Changer' For Weight Loss? Ca…

17:44
Rita Jermyn

SGLT2 Inhibitors: For Heart Failure, Diabetes, and Renal Disease

27:24
Cardiometabolic Health Congress (CMHC)

SGLT2 Inhibitors, GLP1 Receptor Agonists, and Renal Outcomes

Feat. L. Sloan
20:24
Diana Isaacs

Tirzepatide for Type 2 Diabetes

26:49
Diana Isaacs

Tirzepatide Updates

05:08
Susan Brian

The Differences Between the Products of GLP1's and GLP/GIPs

14:19
UChicago Medicine

S-QUAD Therapy and Beyond: HFpEF in 2024

Feat. M. Belkin
06:31
Susan Brian

Discussing Retatrutide: A GIP, GLP-1, and Glucagon Receptor Agonist

05:40
Susan Brian

An Introduction to Tirzepatide for Weightloss

13:33
Dr. Sharmila Ghimire

Daily Oral GLP-1 Receptor Agonist Orforglipron for Adults with Obesi…

Feat. D. Ghimire
19:30
ACC 2022 Conference Coverage

Hot Topics in Heart Failure ACC.22

Feat. N. Ibrahim
36:34
Scripps Health

GLP-1 Hysteria

Feat. S. Harris
49:21
McMaster University Department of Medicine

Semaglutide: Where Are We Now and Where Are We Going?

Feat. S. Boushahri, D. Lazzam, K. MacEachern